Patent reform passes the house.  This version isn't supported by biotech industry groups.  There's a good round up at California Biotech Law Blog.  The main problem, among others, is the limiting of damages for infringement.  Limiting of damages doesn't seem like a smart way to try to deal with over patenting.  Weak patents should not be issued and that reform needs to take place at the USPTO (has this problem been mitigated at all by the KSR decision?).  Huge damages is the only way or small companies to keep big ones with deep pockets from infringing.